Related Experiment Video
Updated: Mar 20, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
Anti-C1q in systemic lupus erythematosus
1Division of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lupus
|June 3, 2016
Summary
Anti-C1q antibodies are crucial biomarkers in autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE). Their detection aids in diagnosing lupus nephritis and monitoring disease activity, though assay standardization remains a challenge.
Area of Science:
- Immunology and Rheumatology
- Autoimmune Disease Biomarkers
- Complement System Research
Background:
- C1q is the initiating component of the classical complement pathway.
- Anti-C1q autoantibodies are detected using ELISA assays, both in-house and commercial.
- These autoantibodies are implicated in various autoimmune conditions.
Purpose of the Study:
- To highlight the clinical significance of anti-C1q antibodies in autoimmune diseases.
- To emphasize the strong association of anti-C1q with lupus nephritis in Systemic Lupus Erythematosus (SLE).
- To discuss the utility of anti-C1q in predicting and monitoring renal involvement in SLE.
Main Methods:
- Detection of anti-C1q antibodies via enzyme-linked immunosorbent assays (ELISA).
- Correlation analysis of anti-C1q titers with disease activity scores and renal flares in SLE patients.
- Evaluation of the negative predictive value of anti-C1q absence for lupus nephritis development.
Main Results:
- Anti-C1q autoantibodies are highly sensitive for hypocomplementemic urticarial vasculitis.
- In SLE, anti-C1q positivity strongly correlates with proliferative lupus nephritis.
- Absence of anti-C1q offers a near 100% negative predictive value for lupus nephritis; titers correlate with disease activity and precede renal flares.
Conclusions:
- Anti-C1q antibodies are valuable serological markers for SLE, especially for renal involvement, in conjunction with anti-dsDNA and low complement levels.
- Monitoring anti-C1q titers can aid in managing disease activity and predicting renal flares in SLE patients.
- The primary barrier to widespread clinical use of anti-C1q is the lack of standardized laboratory assays.
